Congress orders FDA to study hair straighteners and cancer risk in women of color
S. 2285 — Uterine Cancer Study Act of 2025 · Filed by Lisa Blunt Rochester (D-DE) · 2 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services, working with the FDA and National Institutes of Health, to conduct a two-year study on whether chemical hair straighteners increase uterine cancer risk, with special attention to higher rates among women of color. The study will examine existing research, analyze whether different product formulations (dyes, bleach, perms) carry different risks, and determine if the FDA should require additional safety testing before these products reach consumers.
Why we flagged it
The bill's sole function is to authorize and structure a government study into a potential consumer product safety issue. It is a straightforward research directive with no hidden mechanisms or narrow beneficiaries.
What the text implies
- Study results may trigger FDA regulatory action (additional testing, labeling, or restrictions) on hair straightener manufacturers, potentially increasing product development costs and market friction.
- Disaggregation by product type (dyes, bleach, perms) may reveal that certain formulations carry higher risk, creating market segmentation and competitive advantage for manufacturers of 'safer' variants.
The full analysis lists 3 implications of this text.
Who stands to gain
Hair care product manufacturers (potential regulatory clarity or competitive advantage for 'safer' f; Research institutions and contract research organizations (study funding and execution)